Clinical Use of Continuous Glucose Monitoring in Pediatrics.

Abstract

The first reported clinical use of a continuous glucose monitoring (CGM) system in children was by Coss-Buet al. in 1999.1 They investigated a bedside VIA 1-01G Blood Chemistry monitor for measuring glucose in the pediatric intensive care unit (PICU). The monitor was programmed to draw venous blood, analyze, and record blood glucose samples automatically at predetermined intervals. This system was large, difficult to move, required intravenous access, and took 20 min to set up. Nonetheless, the data provided were comparable to measures by a laboratory glucose analyzer and bedside glucometer and could be used to inform clinical decision-making. Many advances have occurred since that time to benefit pediatric patients with diabetes. Most recently, the FDA has approved the Dexcom G5 CGM system for use in insulin dosing decisions (nonadjunctive use),2 the MiniMed 670G hybrid closed-loop system which alters insulin delivery based on CGM data for children ≥14 years of age,3 and the Abbott FreeStyle Libre Pro for use by healthcare providers in tracking glucose data for those 18 years and over.4 In this chapter, published Pediatric data on CGM use will be reviewed in the following areas: type 1 and 2 diabetes mellitus, prediabetes, cystic fibrosis, neonatology, adrenal insufficiency, glycogen storage disease, and critical illness. Data were obtained through review of published works from a PubMed search of “pediatric continuous glucose monitor.” We also review pediatric CGM data from artificial pancreas studies, a rapidly evolving field with great promise to reduce burden and improve glucose control in pediatric patients.